Loreus

	Contact
	Téléphone : Mail : Adresse : INFORMATICS Gervase J-Block, Clifton Campus, Clifton Lane, Nottingham Royaume-Uni Web : http://www.loreus.com

	Consultez cette fiche en intégralité ?
	Consultez cette fiche et près de 50 000 autres fiches de Centres de Recherche dans plus de 30 pays européens sur Expernova.com ! Inscrivez-vous ou contactez-nous pour une démonstration personnalisée. Il s’agit de votre centre de Recherche ? Inscrivez-vous gratuitement et complétez vos informations.

	Profil scientifique partiel

	Quelques documents de Loreus
	European Network for the identification and validation of Antigens and biomarkers in Cancer and their application in clinical Tumour immunology ENACT 2005 - 2008 Sujets : Education, Training, Scientific Research, Social Aspects, Medicine, Health, Life Sciences Other Indexes:biomarkers,prostate cancer,melanoma,tumour progression,ovarian cancer,tumour escape Type de contrat : Specific Targeted Research Project Participants : THE NOTTINGHAM TRENT UNIVERSITY UNITED KINGDOM THE NOTTINGHAM TRENT UNIVERSITY SCHOOL OF SCIENCE, THE NOTTINGHAM TRENT UNIVERSITY Burton Street UNITED KINGDOM UNIVERSITY OF LATVIA, BIOMEDICAL RESEARCH AND STUDY CENTRE LATVIJA UNIVERSITY OF LATVIA, BIOMEDICAL RESEARCH AND STUDY CENTRE Other,Research UNIVERSITY OF LATVIA, BIOMEDICAL RESEARCH AND STUDY CENTRE Ratsupites St 1 LATVIJA JAGIELLONIAN UNIVERSITY, MEDICAL COLLEGE POLSKA JAGIELLONIAN UNIVERSITY, MEDICAL COLLEGE Other INSTITUTE OF MEDICAL BIOCHEMISTRY, JAGIELLONIAN UNIVERSITY, MEDICAL COLLEGE Sw. Anny 12 POLSKA INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE FRANCE INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE Research INSERM U268 101, rue de Tolbiac FRANCE MEDICAL UNIVERSITY HOSPITAL "ALEXANDROVSKA" BULGARIA MEDICAL UNIVERSITY HOSPITAL "ALEXANDROVSKA" Other MEDICAL UNIVERSITY HOSPITAL "ALEXANDROVSKA", CENTRAL LABORATORY OF CLINICAL IMMUNOLOGY Georgy Sofiiski 1 BULGARIA EBERHARD-KARLS-UNIVERSITÄT TÜBINGEN DEUTSCHLAND EBERHARD-KARLS-UNIVERSITÄT TÜBINGEN Other ABT. INNERE MEDIZIN II ZENTRUM FÜR MEDIZINISCHE FORSCHUNG, ZMF UNIVERSITÄTSKLINIKUM TÜBINGEN Wilhelmstr. 5 DEUTSCHLAND KAROLINSKA INSTITUTET SVERIGE KAROLINSKA INSTITUTET Other KAROLINSKA INSTITUTET DEPARTMENT OF ONCOLOGY-PATHOLOGY Karolinska Institutet SVERIGE FUNDACIÓN VIRGEN DE LAS NIEVES ESPAÑA FUNDACIÓN VIRGEN DE LAS NIEVES Other DEPARTAMENTO DE ANALISIS CLINICOS. HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES C/ Dr. Azpitarte s/n. Edificio Licinio de la Fuente ESPAÑA DEUTSCHES KREBSFORSCHUNGSZENTRUM (GERMAN CANCER RESEARCH CENTER) DEUTSCHLAND DEUTSCHES KREBSFORSCHUNGSZENTRUM (GERMAN CANCER RESEARCH CENTER) Other SKIN CANCER UNIT (DO70) Im Neuenheimer Feld 280 DEUTSCHLAND THE NORWEGIAN RADIUM HOSPITAL HF NORGE THE NORWEGIAN RADIUM HOSPITAL HF Other DEP. OF IMMUNOLOGY, INSTITUTE FOR CANCER RESEARCH, SECTION FOR IMMUNOTHERAPY Montebello NORGE THE ANTHONY NOLAN TRUST UNITED KINGDOM THE ANTHONY NOLAN TRUST Other THE ANTHONY NOLAN RESEARCH INSTITUTE THE ROYAL FREE HOSPITAL POND ST UNITED KINGDOM A'PESYP OF ATTICA-SAINT SAVAS CANCER HOSPITAL-CANCER IMMUNOLOGY AND IMMUNOTHERAPY CENTER HELLAS A'PESYP OF ATTICA-SAINT SAVAS CANCER HOSPITAL-CANCER IMMUNOLOGY AND IMMUNOTHERAPY CENTER Other CANCER IMMUNOLOGY AND IMMUNOTHERAPY CENTER, SAINT SAVAS HOSPITAL 3,Zacharof str HELLAS LOREUS United Kingdom LOREUS Industry INFORMATICS Gervase J-Block, Clifton Campus, Clifton Lane, United Kingdom ONYVAX United Kingdom ONYVAX Industry ONYVAX LIMITED St. Georges Hospital Medical School, Cranmer Terrace United Kingdom Hide objective ENACT aims to identify markers of response and tumour antigens that associate with ovarian and prostate cancer and melanoma progression and resistance to immunotherapy. Prospective clinical material will be collected during the life of the programme and new and existing tumour tissue, PBMC and serum banks will be available for use in the study. This common resource of material will be distributed to partners for terminological, genomic, biochemical and polemic analysis of tumour cells and host response(s) toimmunotherapy. The results will be subjected to bioinorganic analysis in the context of clinical outcome of vaccine-based immunotherapy trials from 5 European clinical centres. Analysis of the results in the context offender, will allow prominent inter- and intra- tumour/host biomarkers to be identified and translated back into clinical practice. The combined clinical and scientific expertise of the consortium provides added value and links with two on-going 5th Framework cancer programmes that will allow immediate access to melanoma patient data, tumour tissue and cell lines. This study promotes interdisciplinary transactional research, which will offer a leading role to partners in 3 Eastern European NAS countries and in Sees, and will provide a unique technology and science-driven platform for future expansion. We (the consortium) have extensive experience in the management and operation of 3rd-5th Framework projects and this current programme of research builds on previous experience and collaboration by many of the partners, but also increases the repertoire of scientific expertise byte inclusion of new partners, whose research skills are complimentary to the aims of ENACT. Source : cordis